| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Nurix Therapeutics, Inc. (NRIX) have been net sellers, shedding 49,260 shares worth roughly $1.2M on balance. In the past 30 days, 0 insiders bought and 4 sold.
All 4 insiders who sold still hold shares after their sales.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 123.5K | $3.19M | -6,861 | |
| CFO | 47.5K | $1.23M | -2,834 | |
| Other | 15.3K | $395.9K | -3,957 | |
| Dir | 10.8K | $277.6K | -22,583 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2021 | Gwenn Hansen70 | Chief Scientific Officer | Sale+OE | 800 | $36.27 | $29,018.02 | -6.3% | |
| Feb 18, 2021 | Hans van Houte56 | Chief Financial Officer | Sale+OE | 13,583 | $35.46 | $481,621.05 | - |